Nexvet Biopharma, which is developing biologics for the treatment of pain and inflammation in cats and dogs, raised $40 million by offering 4.0 million shares at $10.00, well below the $13 to $16 range. Nexvet Biopharma will list on the NASDAQ under the symbol NVET. BofA Merrill Lynch and Cowen & Company acted as joint bookrunners on the deal.
